Pfizer Inc
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Orgovyx (relugolix by Year
Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — U.S. revenues ($M) ($M)
Pfizer Orgovyx (relugolix: $421M in FY2025, up 109.5% from a year earlier.
Where the FY2025 figure comes from
“|| Orgovyx (i) | 421 | 201 | * | * | 421 | 201 | * | — | — | — | —”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — U.S. revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 421 | +109.5% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 201 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
Cite this data
StockData. (2026). Pfizer Orgovyx (relugolix ($M), annual FY2024–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/orgovyx-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.
See a number that looks wrong?